ReviewMaterials today. Bio2025
Bioengineering methods for tailoring treatment of Osteomyelitis: Advancing strategies and application.
Review in Materials today. Bio, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Article
- Context-dependent roles of the NLRP3 inflammasome in osteomyelitis and strategies for precision modulation.Frontiers in immunology · 2026Review
- Antibacterial polyphenols for osteomyelitis treatment: from antibacterial mechanisms to biomaterial-based delivery.Frontiers in cell and developmental biology · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Osteomyelitis (OM), an inflammatory disease of the bone due to pathogenic infection, represents one of the most significant challenges encountered by orthopedic surgeons worldwide. Under pathogenic, OM sites undergo persistent inflammation, oxidative stress, bone immune dysfunction, and abnormal osteocyte metabolism, resulting in recurrent bacterial infections and bone resorption. The curation of OM primarily relies on systematic high-dose antibiotics and local surgical debridement. Despite the discovery of various antimicrobial drugs in recent decades, there has been little clinical progress in OM eradication. The emergence of bioengineering materials offers great hope for addressing this issue. Beyond the antimicrobial activity, they often possess one or more of the following functions: antioxidant, anti-inflammatory, immunomodulatory, angiogenic and osteogenic. These materials have shown promising therapeutic effects in animal OM models. However, extensive and comprehensive animal studies and clinical trials are still needed to determine their direct and lasting impact on OM patients. This review integrates the complex microenvironmental characteristics of OM, delving into the construction principles and mechanisms of various bioengineering methods. It aims to enhance understanding of their suitability in meeting the therapeutic needs of OM. Additionally, it explores the clinical applicability and future prospects of multifunctional biomaterials in treating OM.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.